-5%
Siglimet is recommended as an adjunct to diet and exercise to enhance blood sugar control in adults with type 2 diabetes mellitus, especially when combination therapy with sitagliptin and metformin is appropriate.
Not suitable for patients with type 1 diabetes or diabetic ketoacidosis.
Safety has not been established in patients with a history of pancreatitis. It is unclear whether such patients are at higher risk of pancreatitis during treatment.
This combination tablet utilizes two complementary mechanisms to manage blood glucose:
- Sitagliptin (DPP-4 inhibitor): Slows the degradation of incretin hormones (GLP-1 and GIP), enhancing insulin secretion and reducing glucagon levels in a glucose-dependent manner, thereby improving glycemic control.
- Metformin (Biguanide): Lowers glucose production in the liver, reduces intestinal absorption of glucose, and enhances insulin sensitivity in peripheral tissues.
Together, they offer a dual approach to improving glycemic control.